Back to top
more

BeiGene (BGNE)

(Delayed Data from NSDQ)

$198.50 USD

198.50
135,710

+0.34 (0.17%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $198.56 +0.06 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Surprise Coming for BeiGene (BGNE) This Earnings Season?

by Zacks Equity Research

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Down -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a Turnaround

by Zacks Equity Research

BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Anika (ANIK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.

Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.

Will Top-Line Contraction Affect Altice (ATUS) Q4 Earnings?

by Zacks Equity Research

Altice's (ATUS) top line is likely to decline year over year. Macroeconomic uncertainty, stiff competition, rising programming costs per consumer, and a hefty financial burden likely limit its earning potential.

Will Higher Revenues Benefit Keysight (KEYS) Q1 Earnings?

by Zacks Equity Research

Keysight's (KEYS) top-line performance in the first quarter of fiscal 2023 is likely to benefit from solid demand for its electronic design and test solutions and a robust 5G portfolio.

Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Apexigen, Inc. (APGN) and BeiGene, Ltd. (BGNE) have performed compared to their sector so far this year.

Will Top-Line Expansion Aid Cambium (CMBM) Q4 Earnings?

by Zacks Equity Research

Cambium's (CMBM) ongoing innovation efforts, combined with a strong portfolio of fixed wireless broadband and Wi-Fi networking solutions likely to have a positive impact on company's fourth-quarter earnings.

Can Zymeworks (ZYME) Beat Expectations This Earnings Season?

by Zacks Equity Research

In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.

Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.

Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival

by Zacks Equity Research

Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.

What Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug

by Zacks Equity Research

Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.

Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals

by Zacks Equity Research

Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.

BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why BeiGene (BGNE) Might Surprise This Earnings Season

by Zacks Equity Research

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

by Zacks Equity Research

Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

Novartis (NVS) Announces Positive Data on Oncology Drug

by Zacks Equity Research

Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.

Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More

by Zacks Equity Research

Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.

BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

Why Earnings Season Could Be Great for BeiGene (BGNE)

by Zacks Equity Research

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nalak Das headshot

5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week

by Nalak Das

Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.

BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study

by Zacks Equity Research

BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.